Introduction
An understanding of normal cellular function has been gained from research characterizing various signal transduction pathways. Despite these advances, processes responsible for neoplastic transformation of normal cells remain largely undefined. For this reason, many chemotherapeutic regimens currently available are relatively nonspecific and have many toxic side effects. The ultimate goal of signal-transduction-based research is to develop chemotherapeutic drugs that target cancerous cells without affecting nontransformed cells.
Signaling through the Raf/MEK/ERK cascade is relatively well understood [1] [2] [3] [4] [5] [6] [7] [8] [9] and much progress has been achieved in the inhibition of this signaling pathway. 10, 11 In many cases, however, activation of the Raf/MEK/ERK pathway alone is not responsible for oncogenic transformation. Recent evidence has suggested that the PI3K/Akt pathway is a viable target for novel antineoplastic drugs. This review will describe PI3K/Akt pathway signaling and its effects on cell cycle progression, prevention of apoptosis, and malignant transformation. Lastly, several potential anticancer therapies targeting this cascade are discussed.
Aberrant PI3K activity and oncogenic transformation
The relation between dysregulated PI3K activity and cancer is well documented. For example, a mutated form of the p85 subunit of PI3K has recently been isolated in a Hodgkin's lymphoma-derived cell line (CO). 12 The PI3K/Akt pathway has been shown to be the predominant growth-factor-activated pathway in LNCaP human prostate carcinoma cells. 13 PI3K activity has been linked to a variety of human tumors including breast cancer, 14 lung cancer, 15 melanomas, 16 and leukemia 17 among others. Further evidence has shown that Akt (protein kinase B, PKB), a downstream kinase of PI3K, is also involved in malignant transformation. 18 Inhibition of this pathway is a promising approach for novel chemotherapeutic agents.
Cytokine activation of PI3K/Akt pathway
After cytokine activation of a specific receptor, PI3K can be activated by two mechanisms. First, a phosphorylated tyrosine (Y) residue on the receptor serves as a docking site for the p85 regulatory subunit of PI3K. 1 This recruits the catalytic subunit of PI3K, p110, to this complex. Alternatively, upon activation of the receptor by the cognate cytokine, Shc binds the receptor to enable Grb-2 and Sos to form a complex that activates Ras. [19] [20] [21] [22] Ras can then induce membrane localization and activation of the p110 subunit of PI3K, as determined by crystal structure studies. 23 Specifically, this interaction occurs between regions on Ras, known as switch I (residues 33-41) and switch II (residues 63, 64, and 73), which bind to a sequence on PI3K-g referred to as the Ras-binding domain (RBD). 24 It was recently shown that the PI3K regulatory subunit, p85, contains two additional regulatory domains: a GTPase-responsive domain (GRD) that can mediate PI3K activation through binding small GTPases (Ras, Rac1), and an inhibitory domain that can block these binding events. PI3K inhibition can be lifted when certain tyrosine kinases such as Src, Lck, and Abl phosphorylate the S668 residue contained within the inhibitory domain. 25 Different Ras isoforms have also been shown to have varying abilities to activate PI3K. Although Ras molecules are commonly believed to activate both PI3K/Akt and Raf/MEK/ERK cascades, Ha-Ras preferentially activates PI3K and Ki-Ras preferentially activates Raf. 26 Activated PI3K converts phosphatidylinositol (4,5)-phosphate [PI(4,5)P 2 ] into phosphatidylinositol (3,4,5)-phosphate [PI(3,4,5)P 3 ], which results in membrane localization of phosphotidylinositol-dependent kinase-1 (PDK1) via its pleckstrin homology (PH) domain. Akt is also recruited to the lipidrich plasma membrane by its PH domain and is phosphorylated at residues T308 and S473 by PDK1 and an unidentified kinase, respectively ( Figure 1) .
Akt is the primary mediator of PI3K-initiated signaling and has a number of downstream substrates that may contribute to malignant transformation. Some of these substrates are Bad, procaspase-9, I-kB kinase (IKK), CREB, the forkhead family of transcription factors (FKHR/AFX/FOX), glycogen synthase kinase-3 (GSK-3), p21 Cip1 , and Raf. 18 IKK and CREB are activated by Akt phosphorylation, whereas Raf, Bad, procaspase-9, FKHR, and GSK-3 are inactivated. Mechanisms by which Akt modulates activity of these proteins to promote cell survival and cell cycle progression will be discussed in the following sections.
Activity of the PI3K/Akt pathway is negatively regulated by phosphatases. Phosphatase and tensin homologue deleted on chromosome 10 (PTEN), which is also known as mutated in multiple advanced cancers-1 (MMAC1), as well as Src homology 2 (SH2) containing phosphatases 1 and 2 (SHIP-1 and SHIP-2) remove phosphates from PI(3,4,5)P 3 .
27-31 Mutations in these phosphatases that eliminate their activity can lead to tumor progression. Consequently, genes encoding these phosphatases are referred to as antioncogenes or tumor suppressor genes. An overview of the PI3K/Akt pathway is presented in Figure 2 .
Cell cycle overview
Uncontrolled cell division can lead to tumorigenesis. Cell division is coordinated by a number of proteins including cyclins and cyclin-dependent kinases (Cdks). Cdks exist as inactive serine/threonine kinase monomers that become activated when bound to specific cyclins. Cyclins are nuclear proteins that are transiently expressed in order to activate its cognate Cdk. These proteins form complexes that facilitate cell cycle progression through various cell cycle stages ( Figure 3 ). Cdk activities are inhibited by two families of Cdk inhibitors (CKIs). The first CKI family is composed of inhibitors of Cdk4 (INK4),  which are p16  INK4a , p15  INK5b , p18  INK4c , and p19 INK4d . INK4 family CKIs inhibit kinase activity of Cdk4/cyclin D and Cdk6/ cyclin D complexes. 32 The second family is Cip/Kip CKIs, which includes p21 Cip1 , p27 Kip1 , and p57 Kip2 . Cip/Kip family CKIs inhibit a broader set of Cdks, including Cdk2, Cdk4, and Cdk6. 33, 34 The roles that these regulatory proteins play in cell cycle progression can be modulated by PI3K signaling.
p21
Cip1 and PI3K/Akt: cell cycle regulatory effects
As previously discussed, the PI3K/Akt pathway is important for the regulation of cell cycle progression. [35] [36] [37] [38] [39] [40] For instance, the PI3K/Akt pathway is crucial for DNA synthesis in mesenchymal cells 35 and expression of dominant negative (DN) Akt blocks platelet-derived-growth-factor (PDGF)-induced DNA synthesis and cell proliferation. 40 p21 Cip1 was initially thought to be a CKI because it inhibited cell proliferation when overexpressed in human fibroblasts. Evidence gathered by in vitro reconstitution studies showed that p21
Cip1 inhibited activity of most Cdk isoforms. 41, 42 Further investigation has suggested that p21
Cip1 has a more complex role in regulating Cdk activity. Under physiological conditions, p21 Cip1 can bind to Cdk4/cyclin D and Cdk6/cyclin D complexes, and induce their kinase activities from early G 1 until the middle of S phase. 43 In contrast, p21
Cip1 can bind to and inhibit kinase activities of Cdk2/cyclin A and Cdk2/cyclin E complexes from the late G 1 until the S phase.
44,45

Figure 1
Activation of the PI3K/Akt pathway. Two mechanisms by which cytokine receptor activation can result in activation of the PI3K/Akt pathway are indicated. Note that significant activation of this pathway occurs in close proximity to the cell membrane. SH2: Src homology-2 domain; PH: pleckstrin homology domain.
The function of p21
Cip1 during cell cycle progression appears to ensure appropriate Cdk activation. p21 Cip1 may also promote cell survival. Insulin-like growth factor-I (IGF-I) improved survival of C3 myoblasts by inducing p21
Cip1 through an Akt-dependent mechanism. 46 IGF-I induction of cell survival was significantly reduced by expression of antisense p21
Cip1 cDNA. In summary, p21 Cip1 has both positive and negative regulatory effects on cell cycle progression, and is also a regulator of cell survival.
The PI3K/Akt pathway is required for p21 Cip1 induction in human ovarian carcinoma cells. 47 Inactivation of this pathway by drug treatment or DN Akt expression decreased levels of p21 Cip1 . 47, 48 In contrast, expression of a constitutively active Akt mutant increased p21
Cip1 expression. 47 Mechanisms by which the PI3K/Akt pathway regulates p21
Cip1 protein expression were further explored by several groups. It was shown that Akt could directly phosphorylate both T145 and S146 near the carboxyl terminus of p21 Cip1 . [49] [50] [51] [52] As a result of these phosphorylation events, DNA synthesis and Cdk activity were stimulated, and cellular proliferation increased.
In normal cells, p21 Cip1 exists as a complex with a cyclin, a Cdk, and proliferating cell nuclear antigen (PCNA) (Figure 4 ). p21
Cip1 binds PCNA directly and inhibits DNA pol d holoenzyme activity. 53, 54 Phosphorylation of T145 by Akt causes PCNA release from the PCNA/p21
Cip1 /Cdk/cyclin quaternary complex ( Figure 4 ). PCNA can then form a complex with the DNA polymerase d holoenzyme and activator protein-1 (AP-1) to induce DNA synthesis. 49, 52 Cytoplasmic relocalization of p21
Cip1 was observed in fibroblasts upon phosphorylation by Akt; 49 however, this relocalization was not observed in endothelial cells. 52 Furthermore, T145 phosphorylation also decreased binding affinity of p21
Cip1 for Cdk2 by more than 50% in endothelial cells. As a result, inhibition of Cdk2 by p21
Cip1 decreased. 52 Interestingly, it appears that modulation of Cdk activity by Aktinduced p21 Cip1 phosphorylation at T145 was specific for Cdk2 because it had little effect on Cdk4 activity.
Akt can also phosphorylate S146 on p21 Cip1 ( Figure 4 ) 50, 51 . Phosphorylation at this site is associated with increased p21 Cip1 protein stability. p21
Cip1 is normally a short-lived protein with a high proteosomal degradation rate. 55 Phosphorylation of S146 in glioblastoma cell lines significantly prolonged the half-life of p21
Cip1
. 50 Since Akt increases protein levels of both p21
Cip1 and cyclin D 1 , it consequently induces assembly of p21
Cip1 /Cdk4/ cyclin D and p21
Cip1 /Cdk6/cyclin D complexes as well as their associated kinase activities. 50 
Figure 2
Overview of the PI3K/Akt pathway. The PI3K/Akt pathway is activated either by the p85 PI3K regulatory subunit binding to an activated tyrosine residue on the activated IL-3 receptor or by the PI3K p110 subunit binding to activated Ras. Both result in membrane localization of PI3K. Some downstream effects of PI3K activation pathway are shown. PI(4,5)P 2 is phosphorylated by PI3K to yield PI(3,4,5)P 3 , which promotes membrane localization of PDK1 through its PH domain. PDK1 then phosphorylates and activates Akt. Note that, depending on the residue phosphorylated, proteins can either be activated or inactivated by phosphorylation. Proteins activated by S/T or Y phosphorylation are indicated with a black P and a clear circle. Proteins inactivated by S/T or Y phosphorylation are shown with a white P in a black circle. Transcription factors are indicated by diamonds. Phosphatases are indicated by rectangles. Phosphatases that inhibit activity, such as PTEN and SHIP, are indicated in black rectangles. The PP2A phosphatase, which activates Raf, is shown in a white rectangle. Open arrows indicate phosphate groups hydrolyzed by phosphatases.
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PI3K and GSK-3
GSK-3 is a substrate of the PI3K/Akt pathway that is constitutively active in unstimulated cells. GSK-3 phosphorylates numerous proteins, such as glycogen synthase, cyclin D, and c-Myc, which maintains these proteins in an inactive state. 56 Activation of PI3K or Akt can lead to GSK-3 inactivation. 57 Many kinases, including protein kinase C (PKC), p90 RSK , p70
SbK , and Akt, phosphorylate GSK-3 in vitro. However, Akt appears to be the kinase primarily responsible for phosphorylation of GSK-3 at S9 in vivo ( Figure 5 ). 57, 58 Recently, it has been shown that like Akt, GSK-3 also regulates p21
Cip1 protein stability (see Figure 5 ). p21 Cip1 can be degraded through ubiquitin-mediated 59 or ubiquitin-independent pathways. 60, 61 The C8 a subunit of the 20S proteosome directly binds to the carboxy terminus of p21 Cip1 , which is necessary for proteosomal degradation. 61 GSK-3, in its constitutively active state, causes decreased p21
Cip1 protein levels in endothelial cells. 51 Moreover, specific inhibition of GSK-3 with lithium chloride 62, 63 prevents p21 Cip1 degradation and increases its protein level 10-fold. 51 GSK-3 can directly phosphorylate p21 Cip1 on T57 ( Figure 5 ). This phosphorylation event is associated with a higher degradation rate of p21
Cip1 . Furthermore, if GSK-3-induced T57 phosphorylation is inhibited by PI3K/Akt activation, the half-life of p21
Cip1 protein is significantly increased. 51 Interestingly, GSK-3 does not phosphorylate p27 Kip1 , which suggests functional diversity in regulation of these two Cip/Kip family CKIs.
64
PI3K/Akt pathway and p27
Kip1
The PI3K/Akt pathway has also been implicated in altering p27 KIP1 activity. Expression of DN Akt in mesenchymal cells caused transcriptional induction of p27 Kip1 , which led to the inhibition of both Cdk2 activity and DNA synthesis. 65 However, these effects were not observed in an endothelial cell model. 48 Therefore, the effects of PI3K/Akt on p27
Kip1 expression may be cell type specific.
The forkhead family of transcription factors (TFs) has recently been categorized into the forkhead box factor (FOX) family. 66 The FOX family includes AFX/FOXO4, FKHR/FOXO1, and FKHR-L1/FOXO3a. Akt can inactivate FOX TFs through direct phosphorylation of multiple S/T residues 38,67,68 ( Figure 6 ). As a result of these phosphorylation events, proapoptotic genes induced by FOX family transcription factors are downregulated, including both p27 Kip1 and Fas. Thus, the PI3K/Akt pathway prevents cell death by both inducing and repressing gene expression.
Recently, three laboratories almost simultaneously demonstrated that Akt can directly phosphorylate p27
Kip1 on T157 and subsequently abolish its inhibitory activity against Cdk-2. [69] [70] [71] In order to inhibit Cdk-2 kinase activity, p27
Kip1 requires translocation from cytosol to the nucleus so as to bind with Cdk-2. Wild-type p27 Kip1 was observed in both the cytosol and nucleus. A T157A p27
Kip1 mutant, however, exclusively localized in the nucleus was found to be associated with cell cycle arrest. This suggested that T157 of p27 Kip1 is important for nuclear localization and Cdk-2 inhibition. Furthermore, T157 is located within the nuclear localization sequence of p27 Kip1 (amino acids [151] [152] [153] [154] [155] [156] [157] [158] [159] [160] [161] [162] [163] [164] [165] [166] and is contained in a putative Akt consensus phosphorylation site (RXXRXXT 157 D). Using breast cell lines as a model, it was shown that Akt could phosphorylate p27 Kip1 on T157 both in vitro and in vivo. Akt-induced T157 phosphorylation caused retention of p27 Kip1 in the cytoplasm and thus, prevention of cell cycle arrest induced by p27 Kip1 .
PI3K/Akt pathway and cyclin D 1
The PI3K/Akt pathway is also a strong activator of cyclin D 1 , a critical player in cell cycle progression. In a manner similar to that described for p21 Cip1 , cyclin D 1 protein levels are also regulated by GSK-3. Cyclin D 1 degradation occurs mainly through the ubiquitin-dependent proteolysis pathway triggered by phosphorylation 36 ( Figure 7) . In order to be recognized by ubiquitin-conjugating enzymes E1 and E2 for proteolysis, cyclin D 1 must be phosphorylated at T286 near its carboxyl terminus. 36 GSK-3 is the primary kinase that phosphorylates cyclin D 1 at this residue. 36 Moreover, cyclin D 1 phosphorylation at T286 by GSK-3 is also associated with the translocation of cyclin D 1 from the nucleus to the cytoplasm. Rapid cyclin D 1 degradation induced by GSK-3 is inhibited by activation of PI3K/Akt pathway because Akt directly phosphorylates and inactivates GSK-3. Cell cycle overview. The cell cycle is divided into G 1 (gap 1), S (DNA synthesis), G 2 (gap 2), and M (mitosis) stages. The point after which cellular division must occur is referred to as the restriction point (R) and is located at the latter portion of G 1 . Progression through the cell cycle is promoted by formation of Cdk/ cyclin complexes. The relative activity of each complex is represented by the thickness of gray arcs. Regulators of Cdk/cyclin complexes are shown in black.
Figure 4
Phosphorylation of p21 Cip1 by Akt regulates cell cycle progression. Phosphorylation of p21
Cip1 at T145 and S14b by Akt can affect both DNA synthesis and cell cycle progression.
P13K/
Akt pathway as a target for cancer chemotherapy F Chang et al
PI3K/Akt pathway and c-Fos
c-Fos is a transcriptional regulator that can elevate expression of many proliferatory genes. Consequently, its ability to enhance transcription of these genes is strictly controlled. Transfection of NIH-3T3 mouse fibroblast cells with a constitutively active PI3K p110 mutant induced transcription from the c-Fos promoter, which was blocked by cotransfection with DN Ras. 65 Moreover, transfection of rat mesenchymal cells with a DN Akt mutant decreased c-Fos transcription. 67 Induction of c-Fos transcription by PI3K or Akt was mediated by Elk-1. 67 These data suggest that the PI3K/Akt pathway executes some of its antiapoptotic effects through transcription factors such as Elk-1 and c-Fos. These results are intriguing because ERK also phosphorylates Elk-1, which places this transcription factor downstream of both Raf/ MEK/ERK and PI3K/Akt pathways (Figure 8 ). Regulation of p21 Cip1 protein stability by the PI3K/Akt pathway. Effects of Akt on GSK-3 and stability of p21 Cip1 are indicated. Akt can induce GSK-3 phosphorylation, which renders it inactive. Akt can phosphorylate p21 Cip1 , which stabilizes the protein.
Figure 6
Effects of the PI3K/Akt pathway on FOX transcription factors. Akt can phosphorylate and inactivate FOX transcription factors. DN Akt can block this effect to increase expression of p27 Kip1 and Fas, which inhibit cell cycle progression and cause apoptosis, respectively.
Figure 7
Regulation of cyclin D 1 protein stability by the PI3K/Akt pathway. Cyclin D 1 is phosphorylated by GSK-3, which can be prevented by phosphorylation of GSK-3 by Akt. Phosphorylated cyclin D is translocated from the nucleus to the cytoplasm and targeted for degradation by ubiquitination.
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PI3K/Akt pathway and NF-jB
NF-kB is a transcription factor that can be induced by a variety of signals. Inhibitor of kB (I-kB) binds to NF-kB and inactivates it by localizing NF-kB to the cytosol where it is unable to regulate transcription. Phosphorylation of I-kB targets it for ubiquitination and degradation. In the absence of I-kB, NF-kB's nuclear localization signal is exposed and NF-kB localizes to the nucleus where it is able to induce transcription. The role of NF-kB was originally described as a factor associated with apoptosis. Many agents, which induce apoptosis, such as TNF-a, also induce NF-kB activation. 72, 73 However, it was subsequently shown that inhibition of NF-kB activation potentiates apoptosis. [74] [75] [76] [77] In addition, inhibition of I-kB expression by oligonucleotides led to cell transformation. 78 The data now support the concept that NF-kB is an antiapoptotic molecule. Consistent with this role, NF-kB has been shown to induce transcription of antiapoptotic proteins. [79] [80] [81] [82] IKK is known to phosphorylate and induce the degradation of I-kB. 83 Akt is reported to phosphorylate and activate IKK. 84, 85 Activation of IKK causes phosphorylation and degradation of I-kB, which leads to localization of NF-kB to the nucleus, where it can induce transcription of antiapoptotic genes. 85 Thus, Akt can inhibit apoptosis by activating NF-kB.
PI3K/Akt signaling and the Bcl-2 family of proteins
The Bcl-2 family of proteins are structurally related molecules that play an instrumental role in the regulation of apoptosis. This family includes both proapoptotic proteins such as Bad and Bax as well as antiapoptotic proteins such as Bcl-2 and Bcl-X L . The balance of antiapoptotic to proapototic proteins is believed to dictate whether a cell will survive or undergo apoptosis. This concept has been termed the rheostat theory. 86 Raf has been shown to directly phosphorylate Bad and Bcl-2 to exert antiapoptotic effects. 87, 88 However, the role of Raf in apoptosis regulation remains controversial. Depending on cell type as well as apoptotic stimulus, Raf can inhibit [89] [90] [91] [92] [93] [94] [95] [96] or promote 97-99 apoptosis. Mitochondrial Raf-1 inactivates Bad by phosphorylating Bad at S136 100 ( Figure 9 ). Mitochondrial Raf-1 is unable to activate ERK1 or ERK2 and appears to inactivate Bad by a mechanism dependent upon MEK and Akt. In rat hepatocytes, A-Raf has been found to be localized to inner and outer mitochondrial membrane protein import receptors hTOM and hTIM, which suggests that A-Raf may also exert antiapoptotic effects. 101 Akt can modulate Bad activity by phosphorylating S112. 102 Phosphorylated Bad then dissociates from Bcl-2 to form a complex with the 14-3-3 adaptor protein. Dissociation of Bad from Bcl-2 is associated with cell survival. Recent studies have also shown that p70
S6K
, which is also a target of the PI3K/Akt pathway, can also phosphorylate Bad at S112. [103] [104] [105] Furthermore, Raf/MEK/ERK and PI3K/Akt pathways can synergize to induce cell survival and cellular transformation. 5, 6 This may result from phosphorylation of proapoptotic Bad at these two serine residues. It is worth noting that a third residue of Bad is phosphorylated by the PKA pathway. 105 
Interactions between Raf/MEK/ERK and PI3K/Akt pathways
It has been shown that PI3K/Akt and Raf/MEK/ERK pathways can interact in multiple ways. In some cells, Akt can contribute to Raf-1 inactivation (see Figures 2 and 10) . However, phosphorylation of Raf-1 by Akt has not been universally observed and complete inactivation of Raf-1 also requires phosphorylation at other residues such as S621. Since Raf can regulate p21 Cip1 activity, inhibition of Raf by Akt would be expected to reduce p21 Cip1 activity, which could affect cell cycle progression 64,65,67,106-109 (see Figure 10 ). The Raf/MEK/ERK cascade can also activate the PI3K/Akt pathway. We have observed that Raf can activate Akt activity in hematopoietic cells transformed to grow in response to activated Raf in the absence of exogenous cytokines (unpublished data). Others have observed that some antiapoptotic effects of the PI3K/Akt pathway are dependent upon the Raf/MEK/ERK pathway. Even though both pathways can be regulated by Ras, they P13K/Akt pathway as a target for cancer chemotherapy F Chang et al cross-regulate one another to control both apoptosis and cell cycle progression.
Ectopic overexpression of Raf and MEK oncoproteins led to abrogation of cytokine dependence of murine FDC-P1 and human TF-1 hematopoietic cells. 1, [93] [94] [95] [96] [110] [111] [112] It has been postulated that Raf/MEK/ERK signaling can activate the PI3K/ Akt pathway to induce cell survival. The PI3K inhibitor LY294002 and the downstream p70 S6K inhibitor rapamycin are potent inhibitors of Raf-mediated proliferation, suggesting that some effects of Raf on cell growth are mediated by the PI3K/Akt/ p70 S6K pathway as discussed later. The issue is complicated because many Raf-transformed cells express autocrine cytokines that activate the PI3K/Akt pathway. However, we have observed that Raf could induce PI3K acivity in cytokine-dependent cells that do not secrete autocrine growth factors.
Crosstalk between these two pathways has been demonstrated. It has been shown that Akt can directly phosphorylate Raf isoforms within their CR2 amino-terminal regulatory domain. These sites include S259 on Raf-1 and both S364 and S428 on B-Raf. Serine-phosphorylated Raf molecules then become inactivated by binding to the 14-3-3 adaptor protein. [113] [114] [115] The inhibitory effect of Akt on Raf activity appears to be dependent upon cell type and stage of differentiation 116, 117 because some investigators have not observed this effect. Certain differentially expressed mediators may be essential for association of Akt and Raf.
Recently, a negative feedback loop has been identified involving Raf/MEK/ERK and PI3K/SGK pathways. 118 Serum and glucocorticoid-inducible kinase (SGK) shares a high homology with Akt. 119 Even though physiological targets of SGK and their function(s) remain largely unknown, regulation of SGK has been documented. SGK shares a regulatory pathway with Akt. Like Akt, SGK can be activated by PI3K [120] [121] [122] even though it lacks a PH domain. Secondly, both Akt and SGK are directly phosphorylated and activated by PDK1. 119, 122 Interestingly, SGK and Akt phosphorylate different residues of FKHR-L1 and synergistically inactivate B-Raf.
Using murine FDC-P1 hematopoietic cells as a model, we have determined that Raf activation led to G 1 progression in association with downregulation of p27 Kip1 and upregulation of p21 Cip1 protein levels. 64 Although Cdk4/cyclin D/p21
Cip1 complex formation was detected, no binding was observed between p21 Cip1 and Cdk2/cyclin E or between p27 Kip1 and Cdk4/cyclin D or Cdk2/cyclin E. The increases in p21 Cip1 protein levels and binding of p21
Cip1 with Cdk4/cyclin D complexes induced by Raf were correlated with increased Cdk4 kinase activity. 64 Our results suggest that, in hematopoietic cells, Raf signaling increases levels of p21
Cip1 protein, which then specifically binds to and activates the Cdk4/cyclin D complex. The fact that p27 Kip1 was found not to associate with Cdk2 or Cdk4 suggested that, at least in our model system, p27 Kip1 has little effect on Cdk2 or Cdk4 kinase activity. This finding is interesting because it suggests that Raf activation differentially regulates p21
Cip1 and p27 Kip1 activities. Thus, p21
Cip1 and p27 Kip1 appear to have similar, yet unique functions.
Involvement of the PI3K/Akt pathway in neoplasia
The PI3K pathway is negatively regulated by phosphatases. PTEN is considered a tumor suppressor gene. 123 PTEN is a dual specificity lipid and protein phosphatase that removes the 3-phosphate from the PI3K lipid product PI(3,4,5)P 3 to yield Figure 10 Interactions between PI3K/Akt and Raf/MEK/ERK pathways. Potential sites of interaction between these two pathways are indicated. These pathways interact and cross-regulate each other by both direct and indirect mechanisms. These pathways regulate gene expression by transcriptional, post-transcriptional, and post-translational mechanisms.
P13K/Akt pathway as a target for cancer chemotherapyPI(4,5)P 2 , which prevents Akt activation. [124] [125] [126] [127] Recently, SHIP-2, has been shown to remove the 5-phosphate from PI(3,4,5)P 3 to yield PI(3,4)P 2 . 128, 129 Aberrant proliferative and antiapoptotic signals transduced by the PI3K/Akt pathway have been linked to malignant transformation. 130 Ras can activate PI3K and some Ras mutations cause deregulated activation of PI3K and Akt. [131] [132] [133] Since PTEN and SHIP-2 negatively regulate PI3K activity, loss of their phosphatase activity may also induce Akt activation. [134] [135] [136] Mutations and hemizygous deletions of PTEN have been detected in primary acute leukemia and non-Hodgkin's lymphoma. In addition, many hematopoietic cell lines lack or have low PTEN protein expression. 134, 135 Increased Akt expression has also been linked with tumor progression. Akt-2 gene amplification has been observed in some cervical, ovarian, and pancreatic cancers as well as non-Hodgkin's lymphomas. [136] [137] [138] [139] SHIP-1 may also affect Akt activity by controlling levels of PI(3,4,5)P 3 and PI(3,4)P 2 . If SHIP-1 activitiy is lost, PI(3,4,5)P 3 levels would be elevated, leading to Akt phosphorylation at T308 by PDK1. Conversely, PI(3,4)P 2 levels would be decreased, which would prevent activation of the unidentified kinase responsible for Akt phosphorylation at S473. 140 Thus, this pathway is regulated such that cetain mutations would cause partial, but not complete, Akt activation.
PI3K/Akt pathway as a target for chemotherapy
Inhibition of the PI3K/Akt pathway could prevent uncontrolled cellular proliferation. Consequently, antiapoptotic signals transduced by PI3K and downstream molecules have become a focus of recent drug discovery research. This section will discuss strategies that have been used to inhibit this pathway.
Small molecule inhibitors (SMIs) have been discovered for many kinases involved in various signal transduction pathways ( Figure 11 ). For example, quercetin is marketed by Calbiochem (San Diego, CA, USA) as an inhibitor of PI3K. However, its specificity has been questioned because it has also been found to inhibit other serine/threonine kinases such as AMPK, CK2, p90 RSK2 , and p70 S6K1 . 141 2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) and wortmannin are two widely used PI3K inhibitors. Of these two, LY294002 is more specific and is therefore more commonly used than wortmannin. 141 LY294002 is a quercetin derivative with a reported IC 50 value of 1.4 mm. 142 Wortmannin is a fungal metabolite with an IC 50 value of 5 nm. 143 Akt inhibitors have been recently discovered. One is 1L-6-hydroxymethyl-chiro-inositol 2-(R)-2-O-methyl-3-O-octadecylcarbonate, which is marketed by Calbiochem. It has been reported to inhibit selectively Akt with an IC 50 value of approximately 5 mm, which is much less than its IC 50 value of 90 mm for PI3K inhibition. 144 Additionally, it was recently reported that the tyrosine phosphorylation inhibitor (tyrphostin) AG957, which is also named NSC 654705, caused dephosphorylation of Akt. 145 This report is intriguing because AG957 was previously described as an inhibitor specific for the Bcr-Abl chromosomal translocation gene product implicated in development of chronic myelogenous leukemia (CML). p70 S6K is another viable target for chemotherapeutic intervention within the PI3K/Akt pathway. Rapamycin is commonly used to inhibit p70 S6K activity. It is a macrolide antibiotic produced by the filamentous bacterium Streptomyces hygroscopicus. 146 Rapamycin is used as a powerful immunosuppressant, which has been effective in a variety of clinical settings such as organ transplantation. Rapamycin dephosphorylates p70 S6K at sites different from those associated with activation.
147
As a consequence, phosphorylation of the S6 ribosomal protein necessary for cell growth does not occur. Transfection with plasmid-based antisense vectors or treatment with synthetic antisense oligonucleotides have also been used to disrupt signaling by the PI3K/Akt pathway. Antisense nucleic acids inhibit translation by hybridizing to complementary mRNA transcripts to prevent ribosome binding. Skorski et al 148 showed that expression of antisense cDNA or treatment with antisense oligonucleotides downregulated p85 gene expression and abrogated PI3K signaling. Antisense RNAs were found to drastically reduce tumorgenicity of PANC1 cells, which overexpress Akt2, in nude mice. 149 Antisense oligonucleotides targeted to Akt1 had several effects on a variety of cancer cell lines, including reduced ability to grow on soft agar, induction of apoptosis, and enhanced susceptibility to various chemotherapeutic agents. 150 Similar results were obtained from studies of antisense oligonucleotides targeted to PDK1. 151 Earlier in this review, it was discussed that PI3K is a known downstream substrate of the GTPase Ras. Disruption of Ras activity may also be effective for inhibition of the PI3K/Akt pathway. Three approaches that have been taken to inhibit Ras signaling include prevention of Ras membrane localization, antisense strategies, and ectopic expression of DN proteins.
Membrane localization of Ras has been inhibited with farnesyltransferase inhibitors (FTIs). Ras becomes active only after post-translational addition of farnesyl or geranylgeranyl isoprenoid moieties to its carboxy terminus. Without such P13K/Akt pathway as a target for cancer chemotherapy F Chang et al modification, Ras remains in the cytosol where it cannot activate PI3K. Enzymes catalyzing transfer of these lipid moieties to Ras include farnesyltransferase (FT), geranylgeranyltransferase type I (GGTI), and geranylgeranyltransferase type II (GGTII). An abundance of FTIs are currently available for laboratory use. Chemical structures of some FTIs are shown in Figure 12 . For example, arglabin-DMA is a recently discovered FTI that is derived from a species of wormwood endemic to central Asia. 152 There are currently four FTIs undergoing clinical trials: R115777, SCH66336, L-778,123, and BMS-214662. 153 , 154 Jiang et al 155 reported that apoptosis caused by FTI-277 could be rescued through expression of a constitutively active form of Akt, suggesting that FTIs may mediate some inhibitory effects not only through the Ras/Raf/MEK/ERK pathway, but also the PI3K/Akt signaling cascade.
Antisense strategies have also been used to disrupt Ras. Expression of antisense K-Ras cDNA suppressed the malignant phenotype of large cell lung carcinomas 156 and inhibited growth of H460a lung cancer cells nearly three-fold. 157 ISIS 2503 is a 20-base antisense phosphorothioate oligodeoxyribonucleotide targeting H-Ras that is currently in phase 2 clinical trials. 158, 159 Lastly, expression of DN proteins has been used to inhibit Ras signaling. DN proteins bind and inhibit function of endogenous proteins. Two DN forms of Ras have been described. The first, Ras17N, blocks endogenous Ras GTPase activity, which is essential for signal transduction. 160, 161 Ras17N has been described to inhibit Akt activation elicited by the v-Crk oncogene. 162 Another DN mutant binds endogenous Ras to form inactive complexes localized to the cytoplasm. Signals from the plasma membrane are not transduced by Ras because its localization to the plasma membrane is disrupted. 163 Inhibition of both PI3K and Akt has also been achieved with DN proteins. Expression of a DN form of p85, Dp85, decreased cell growth in Bcr-Abl-transformed cells. 164 Another report described use of a DN form of p110, the catalytic subunit of PI3K. 165 Furthermore, Mabuchi et al 166 reported that ovarian cancer cells become sensitized to paclitaxel by DN Akt expression.
Lastly, PI3K signaling can be abrogated through the activity of two known phosphatases. SHIP-2 overexpression has been observed to cause Akt inactivation and cell cycle arrest in glioblastoma cells. 167 Overexpression of PTEN inhibits proliferation and malignant progression of prostate cancer cells. 168 Taken together, these data indicate that phosphatases may have therapeutic promise by abrogating signaling transduced through PI3K. Strategies for inhibiting the PI3K/Akt pathway are outlined in Figure 13 .
Summary
In this review, we have discussed the effects of the PI3K/Akt pathway on cell cycle progression and apoptosis. This pathway plays critical roles in cell proliferation, oncogenesis, and its activity is regulated positively by Ras and negatively by PTEN. The PI3K/Akt pathway can induce cell cycle progression by modulating the protein stability of cyclin D and p21
Cip1 . Akt can directly phosphorylate p21
Cip1 on S146 and increase its protein stability. Alternatively, Akt can also prolong the half-life of both p21
Cip1 and cyclin D through inactivation of GSK-3, which phosphorylates p21
Cip1 and cyclin D to induce their degradation. Akt facilitates this inactivation event via phosphorylation of GSK-3 on residue S9. The PI3K/Akt pathway can also induce DNA synthesis. When T145 of p21
Cip1 is phosphorylated by Akt, DNA pol d is released from p21
Cip1 and binds with AP-1 to induce DNA synthesis. Recently, Akt has also been shown to directly phosphorylate p27 Kip1 on T157 to cause its retention in the cytosol. As a result, p27
Kip1 loses its inhibitory effect on Figure 12 Farnesyltransferase inhibitors. Chemical structures of commonly used FTIs are shown.
Cdk2. Moreover, phosphorylation of FKHR-L1 by Akt also leads to reduced p27 Kip1 transcription. The PI3K/Akt pathway also regulates activity of Bcl-2 family members. Both Akt and p70 S6K can phosphorylate proapoptotic Bad, which promotes association of Bad with 14-3-3 adaptor protein and allows excess Bcl-2 or Bcl-X L to out compete Bax, there by preventing apoptosis.
It is becoming increasingly evident that interactions between the PI3K/Akt and Raf/MEK/ERK pathwys are important for the regulation of cell cycle progression and apoptosis. Some scientists have observed that Akt phosphorylates Raf-1 on S259 to inhibit its kinase activity, and these inhibitory effects may be released by removal of this phosphate by protein phosphatase 2A. However, these interactions remain controversial because they have not been unequivocably confirmed by other investigators. Future studies into these types of biomolecular interactions are, therefore, warranted.
Despite the tremendous amount of research that remains uncompleted, it is evident that signal transduction pathways interact to regulate cell cycle progression and apoptosis. An understanding of how these different cascades control expression of cell cycle regulatory genes by transcriptional and posttranscriptional mechanisms may reveal novel strategies to prevent their aberrant activation in transformed cells. It is hopeful that further characterization of pathways regulating cell cycle progression and apoptosis will facilitate development of chemotherapeutic inhibitors that will suppress hyperactivity of these cascades and thus prove effective for cancer treatment.
Figure 13
Sites of inhibition of the PI3K/Akt pathway. Schematic overview of the potential negative regulators of PI3K/Akt signaling. Black boxes indicate mechanisms of inhibition.
